ESKALITH (lithium carbonate) by Enthera Pharmaceuticals is 12. First approved in 1979.
Drug data last refreshed 14h ago · AI intelligence enriched 5d ago
ESKALITH (lithium carbonate) is an oral small-molecule mood stabilizer approved in 1979 for bipolar disorder management. The exact mechanism of action remains unknown, though lithium exhibits mood-stabilizing properties in psychiatric populations. It is completely absorbed in the upper GI tract and primarily excreted unchanged in urine with an 18–36 hour half-life.
LOE-approaching lifecycle signals declining commercial team investment and consolidation toward generic stewardship and market access roles rather than growth-stage promotional infrastructure.
12.1 Mechanism of Action The mechanism of action of lithium as a mood stabilizing agent is unknown. 12.3 Pharmacokinetics Absorption: After oral administration, lithium is reported to be completely absorbed in the upper gastrointestinal tract. Peak serum concentrations (T max ) occur 0.25 to 3…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
Bioequivalence Study of Lithium Carbonate 300 mg Tablets. Actilitio® in Healthy Subjects
Worked on ESKALITH at Enthera Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on ESKALITH in its LOE-approaching phase offers limited career acceleration; roles emphasize cost containment, payer strategy, and generic stewardship rather than promotional growth or clinical innovation. This is a defensive, mature-product assignment best suited for professionals building expertise in managed care negotiations and post-patent-life portfolio management.